Biocon And Mylan Get CRL From FDA For Lantus Rival

 
• By Penelope MacRae

Biocon has run into fresh trouble with the US Food and Drug Administration after receiving a complete response letter on its application for insulin glargine, a proposed rival to Sanofi’s top-selling Lantus biologic. 

FDA
The FDA has issued a CRL on Biocon's insulin glargine • Source: Shutterstock

More from Biosimilars

More from Products